CJC-1295 no-DAC + Ipamorelin Blend (5 mg + 5 mg Vial) Dosage Protocol
CJC-1295 + Ipamorelin combines a GHRH analog (5 mg) with a selective GHRP (5 mg) in a single vial — pairing GH-releasing-hormone stimulation with growth-hormone-secretagogue amplification for synergistic pulsatile GH release.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
| Week | Daily Dose (mcg each) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg each | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg each | 4.5 units (0.045 mL) |
| Weeks 5–6 | 200 mcg each | 6 units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
Frequency: Inject once daily subcutaneously, typically before bed or upon waking. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (CJC-1295 NO DAC + Ipamorelin, 10 mg blend each) | 8 weeks ≈ 3 vials 12 weeks ≈ 4 vials 16 weeks ≈ 5 vials |
| Insulin Syringes (U-100, 30- or 50-unit preferred for low volumes) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100-count boxes 12 weeks: 168 swabs → recommend 2 × 100-count boxes 16 weeks: 224 swabs → recommend 3 × 100-count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
This blend pairs CJC-1295 without DAC (a GHRH analog) with ipamorelin (a selective GHRP / ghrelin mimetic). The two work through complementary pituitary pathways: CJC-1295 binds GHRH receptors on somatotrophs to trigger GH release; ipamorelin binds GHS-R receptors and amplifies the GHRH-driven pulse.
The combination produces larger GH pulses than either component alone, mimicking the body’s natural pulsatile pattern. Ipamorelin's selectivity (no significant cortisol or prolactin elevation) makes the blend cleaner than older GHRPs like GHRP-2 or GHRP-6.
Potential Benefits & Side Effects
Potential Benefits
- Synergistic GH pulse — larger than either component alone.
- Pulsatile pattern mimics physiological GH rhythm.
- Ipamorelin selectivity avoids cortisol/prolactin spikes.
- Often combined with pre-bed dosing for sleep-quality benefits.
Side Effect Profile
- Injection-site reactions.
- Mild head flushing post-dose.
- Transient hunger increase (ghrelin pathway).
- Mild fluid retention.
Lifestyle Factors
- Avoid eating for 30+ minutes after injection.
- Pre-bed timing aligns with natural overnight GH pulse.
- Resistance training amplifies outcomes.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm.
- Rotate sites with each dose.
- 90° angle with short insulin needle.